More specifically, and according to our models, dexamethasone is able to modulate COVID-19 evoked ARDS through pathways with wide effects in inflammation, such as those activated by NF-κB, IL-1β and TNFα [69]. The gene discussed is NFKB1; the disease is acute respiratory distress syndrome.